Johnson & Johnson Covid-19 vaccine enters Phase 3 trial in U.S.

Automatic TRANSCRIPT

And Johnson announces data from the Phase one and phase two stages of its covert 19 vaccine. Clinical trials. CBS NEWS Medical contributor. Dr David Vega says the drug resulted and good immune response. NCIS. So now the company says it will do a late stage study of up to 60,000 people. Is that good? I mean responses and safety profile in the phase one trial, the first component of slightly more than 1000 adults, and now the nexus to see what happens with the face. Three. Does it actually Protect. Does this mean response? Protect you from being sick or symptomatic from Cove in 19. Johnson and Johnson's vaccine is one rather than two shots, as are some of the other vaccines currently being studied and further investigated.

Coming up next